Our findings indicate that IL-17A induces CCL20 and CCR6 in the tumor tissues, which then recruit the tumor antigen-loaded DCs to activate the anti-tumor CD8+ T cells.23 RANKL also promotes the differentiation of the immature DCs to the active DCs and is therefore vital for antigen presentation and T cell activation.36,37 Taken together, IL-17A elicits an anti-tumor response by activating the CCL20-CCR6 and RANKL-RANK pathways. The gene discussed is IL17A; the disease is neoplasm.